Status:
RECRUITING
Identification of New Biomarkers for Patients With Cholangiocarcinoma and Gallbladder Cancer
Lead Sponsor:
Herlev and Gentofte Hospital
Conditions:
Biliary Tract Cancer
Cholangiocarcinoma
Eligibility:
All Genders
18+ years
Brief Summary
No validated biomarkers exist that can identify patients with biliary tract cancer at an early stage or predict treatment outcomes. The objective of the present study is to find diagnostic, prognostic...
Detailed Description
Biliary tract cancer (BTC) is a heterogeneous disease and includes both gallbladder cancer and cholangiocarcinoma. Combined BTC is the fifth most common gastrointestinal cancer. The prognosis is poor ...
Eligibility Criteria
Inclusion
- Histological or cytological diagnosis of BTC
- Patients referred for treatment of BTC
- Signed informed consent
Exclusion
- None
Key Trial Info
Start Date :
January 1 2015
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2030
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT05184400
Start Date
January 1 2015
End Date
December 31 2030
Last Update
January 11 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Herlev & Gentofte Hospital
Herlev, Copenhagen, Denmark, 2700